Top

Published in:

01-01-2009 | Preclinical Study

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

Authors: Monzur Rahman, Sean R. Davis, Janet G. Pumphrey, Jing Bao, Marion M. Nau, Paul S. Meltzer, Stanley Lipkowitz

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands.

Available only for authorised users

Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59(3):734–741PubMed

Chinnaiyan A, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97(4):1754–1759PubMedCrossRef

Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5(2):157–163PubMedCrossRef

Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29):7350–7360PubMedCrossRef

Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S (2001) Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61(12):4892–4900PubMed

Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527PubMedCrossRef

Gentleman RC, Carey VJ, Bates DM et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80PubMedCrossRef

Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman RC et al (eds) Bioinformatics and computational biology solutions using R and Bioconductor. Springer, New York, pp 397–420

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a pratical and powerful approach to multiple testing. J R Stat Soc 57:289–300

10.

Ethier SP (1996) Human breast cancer cell lines as models of growth regulation and disease progression. J Mammary Gland Biol Neoplasia 1(1):111–121PubMedCrossRef

11.

Flanagan L, Van Weelden K, Ammerman C, Ethier SP, Welsh J (1999) SUM-159PT cells: a novel estrogen independent human breast cancer model system. Breast Cancer Res Treat 58(3):193–204PubMedCrossRef

12.

Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2(6):420–430PubMedCrossRef

13.

Weinberg RA (2007) The biology of cancer. Garland Science, New York

14.

Charafe-Jauffret E, Monville F, Bertucci F et al (2007) Moesin expression is a marker of basal breast carcinomas. Int J Cancer 121(8):1779–1785PubMedCrossRef

15.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3):319–326PubMedCrossRef

16.

Korsching E, Packeisen J, Agelopoulos K et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82(11):1525–1533PubMed

17.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264–271PubMedCrossRef

18.

Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB (2002) Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res 62(2):488–496PubMed

19.

Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL (1999) Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274(25):17612–17618PubMedCrossRef

20.

Park SY, Seol DW (2002) Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295(2):515–518PubMedCrossRef

21.

Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267(5205):1782–1788PubMedCrossRef

22.

Filmus J, Pollak MN, Cailleau R, Buick RN (1985) MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128(2):898–905PubMedCrossRef

23.

Lebeau J, Goubin G (1987) Amplification of the epidermal growth factor receptor gene in the BT20 breast carcinoma cell line. Int J Cancer 40(2):189–191PubMedCrossRef

24.

Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25(15):2273–2284PubMedCrossRef

25.

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef

26.

Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY (2005) Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep 14(2):337–343PubMed

27.

Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11(22):8006–8014PubMedCrossRef

28.

Hughes SC, Fehon RG (2007) Understanding ERM proteins – the awesome power of genetics finally brought to bear. Curr Opin Cell Biol 19(1):51–56PubMedCrossRef

29.

Wagner KW, Punnoose EA, Januario T et al (2007) Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13(9):1070–1077PubMedCrossRef

30.

Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC (2002) Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 8(2):361–367PubMed

31.

Holland SJ, Powell MJ, Franci C et al (2005) Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 65(20):9294–9303PubMedCrossRef

32.

Evtimova V, Zeillinger R, Weidle UH (2003) Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling. Tumour Biol 24(4):189–198PubMedCrossRef

33.

Shipitsin M, Campbell LL, Argani P et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3):259–273PubMedCrossRef

34.

Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280(3):2205–2212PubMedCrossRef

35.

MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65(24):11265–11270PubMedCrossRef

36.

vander Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 103(23):8634–8639PubMedCrossRef

Title: TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
Authors: Monzur Rahman
Sean R. Davis
Janet G. Pumphrey
Jing Bao
Marion M. Nau
Paul S. Meltzer
Stanley Lipkowitz
Publication date: 01-01-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-9924-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

Donor-derived breast cancer in a bone marrow transplantation recipient

Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial

Germline RAP80 mutations and susceptibility to breast cancer

Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis

Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer